Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.
In this month's "Virtual Lecture," Ann Moyer, M.D., Ph.D. describes how Pharmagenomic and therapeutic drug monitoring tools aid medical providers in selecting drugs and doses to maximize efficacy while minimizing toxicity for mental illnesses, including depression.
Ann Moyer, M.D., Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
This "Specialty Testing" webinar will provide an overview of evidence-based applications of pharmacogenomics, share recent advances, and discuss the clinical utility of new panels and single-gene tests.
Pharmacogenomic testing is still limited, despite ample research, the existence of guidelines, and the emerging evidence it can help patients. Ann Moyer, M.D., Ph.D., Co-Director of the Personalized Genomics Laboratory at Mayo Clinic in Rochester, Minnesota, makes a case for pharmacogenomics.
Ann Moyer, M.D., Ph.D., discusses the importance of pharmacogenomics testing to limit adverse drug reactions and the new focused pharmacogenomics panel available through Mayo Medical Laboratories.